On Demand 2025 Sunday PM General Sessions

This collection covers general sessions from Sunday's afternoon program. This includes plenaries, and symposia. The sessions listed below are included in this package:

  • Allergen Immunotherapy: Safety Considerations From the 2025 JTF Immunotherapy Practice Parameter
  • Managing Chronic Urticaria With Current and Future Biologics and Small Molecules
  • Multifaceted Approach to Patients with AERD and CRSwNP
  • Unmet Needs and Future Directions in Food Allergy
  • Is There a Doctor on the Plane?
  • Envisioning Integrative Medicine Therapies in Allergy Practice
  • Persistent Problems, Unified Solutions: A Multidisciplinary Approach to Chronic Cough
  • The Evolution of Secondary Immunodeficiency

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 10.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Consider the risks, benefits, advantages, and drawbacks of prescribing epinephrine to AIT patients.
  • Develop a strategy for counseling patients who take these medications about the risks/benefits/alternatives regarding AIT.
  • Identify practical considerations for why a practice might/might not offer alternative schedules for aeroallergen and/or venom AIT.
  • Understand the roles of inflight professionals during an emergency and available emergency resources.
  • Develop strategies to successfully transport and utilize biologics and other injectable medications when on vacation.
  • Outline the outcomes of participating in an in-flight emergency.
  • Illustrate the potential benefits and risks of using a selective BTK inhibitor for management of CSU.
  • Evaluate the recent data on the efficacy and safety of KIT inhibitors.
  • Examine the use of biologics for CSU and how it may change our approach when evaluating patients.
  • Understand when aspirin therapy after desensitization is appropriate and ideal for patients.
  • Discern when topical steroids and leukotriene modifying agents should be used and discuss the various forms of application of these products.
  • Describe situations when biologics should be considered and advantages/disadvantages against other therapies.
  • Describe current challenges and barriers to prevention strategies for food allergy. Determine novel diagnostic modalities for food allergy and their application in the clinic setting.
  • Interpret current unmet needs and gaps in food allergy therapies.
  • Relate patient-reported outcomes in food allergy.
  • Distinguish between evidence based integrative therapies and those marketed to consumers without sound clinical data. Describe at least 2 ayurvedic therapies that can be employed in allergy practice and how to collaborate with trained ayurvedic practitioners to improve quality of care for shared patients.
  • Decipher how allergic disease and mental health affect each other and how to screen and intervene with integrative therapeutics to improve quality of life.
  • Identify the effect of lifestyle factors (i.e., sleep, exercise, travel, diet, mind body practices) on microbiome diversity, pathology and health.
  • Describe the neural pathways and mechanisms that lead to chronic cough.
  • Develop a differential diagnosis, diagnostic approach, and treatment plan for patients presenting with chronic cough.
  • Recommend medical and surgical treatment options for patients with chronic cough.
  • Recognize secondary immune deficiencies that can result from B cell depletion therapies.
  • Distinguish secondary immune deficiencies that can result from immunomodulatory therapies that do not include B cell depletion.
  • Formulate effective screening and management strategies for patients receiving immunomodulatory and immunosuppressive therapies.
     
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 10.50 AMA PRA Category 1 Credit™
  • 10.50 Attendance
  • 10.50 CBRN
Course opens: 
11/24/2025
Course expires: 
12/07/2028
Part of: 
On Demand ACAAI 2025 Annual Scientific Meeting
Rating: 
0

Tolly E. Epstein, MD, MS, FACAAI
Michael R. Nelson, MD, PhD, FACAAI
Joseph P. Forester, DO, FACAAI
Paulo M. Alves, MD, MSc, FAsMA
William C. Anderson, III, MD, FACAAI
Sangeetha M. Kodoth, MD, FACAAI
Sarbjit S. Saini, MD
David M. Lang, MD, FACAAI
Nicole M. Chase, MD, FACAAI
Andrew A. White, MD, FACAAI
Shyam R. Joshi, MD, FACAAI
Whitney Stevens, MD, PhD, FACAAI
David M. Fleischer, MD, FACAAI
Wayne G. Shreffler, MD, PhD
Philippe Bégin, MD, PhD
Matthew Greenhawt, MD, MBA, MSc, FACAAI
Dipa K. Sheth, MD, FACAAI
Payel Gupta, MD, FACAAI
Sahar Faghih, MD
Deepa M. Grandon, MD, FACAAI
Peter V. Dicpinigaitis, MD
Joseph K. Han, MD 
Peter J. Kahrilas, MD
Sara Barmettler, MD
Antoine E. Azar, MD
S. Shahzad Mustafa, MD, FACAAI

Available Credit

  • 10.50 AMA PRA Category 1 Credit™
  • 10.50 Attendance
  • 10.50 CBRN
Please login or create an account to take this course.